首页> 外文期刊>Breast cancer research and treatment. >Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast
【24h】

Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast

机译:在诊断为乳腺导管癌的患者中可能检测到血源性和淋巴瘤细胞扩散

获取原文
获取原文并翻译 | 示例
           

摘要

Tumor cell dissemination in bone marrow (BM) and lymph nodes is considered an important step in systemic disease progression and is associated with poor prognosis. Only invasive cancers are assumed to shed isolated tumor cells (ITC) into the bloodstream and infiltrate lymph nodes. However, latest studies indicate that tumor cell dissemination may occur before stroma invasion, i.e., in ductal carcinoma in situ (DCIS). Therefore, the purpose of this study was to examine the incidence of ITC in bone marrow and sentinel lymph nodes (SN) in patients diagnosed with DCIS and its correlation with clinicopathological factors. 266 patients who were treated at the Department of Gynecology and Obstetrics (University Hospital Tuebingen, Germany) between 2003 and 2009 with DCIS were included into this study. BM aspirates were analyzed by immunocytochemistry (pancytokeratin antibody A45-B/B3) using ACIS system (Chromavision) according to the ISHAGE evaluation criteria. SN were analyzed in 221 of these patients by extensive step sectioning and hematoxylin-eosin staining. In 34 of 266 patients (13%), ITC in BM could be detected. There was no correlation found between tumor size, grading, histology, or Van Nuys Prognostic Index and tumor cell dissemination. In two cases, metastatic spread into lymph nodes was observed (pN1mi), whereas in one case, ITC in lymph nodes were detected; however, additional sectioning and immunohistochemical staining of the primary lesion in the cases with positive SN did not reveal invasive cancer. Interestingly, all the three patients were BM negative. Tumor cell dissemination may be detected in patients diagnosed with DCIS. Either these cells have started already to disseminate from preinvasive mammary lesions or from occult invasive tumors or represent the earliest step of microinvasion in a preinvasive lesion. The clinical relevance of these cells has to be further evaluated.
机译:骨髓(BM)和淋巴结中的肿瘤细胞扩散被认为是全身性疾病进展的重要步骤,并且与不良预后有关。假定只有浸润性癌症才能使孤立的肿瘤细胞(ITC)进入血液并浸润淋巴结。但是,最新研究表明,肿瘤细胞的扩散可能发生在基质侵袭之前,即在导管原位癌(DCIS)中。因此,本研究的目的是检查诊断为DCIS的患者中ITC在骨髓和前哨淋巴结(SN)中的发生率及其与临床病理因素的相关性。纳入2003年至2009年期间在德国图宾根大学附属医院妇产科接受DCIS治疗的266例患者。根据ISHAGE评估标准,使用ACIS系统(Chromavision)通过免疫细胞化学(全细胞角蛋白抗体A45-B / B3)分析BM抽吸物。通过广泛的分段切片和苏木精-伊红染色对这些患者中的221名进行了SN分析。在266例患者中的34例(13%)中,可以检测出BM中的ITC。在肿瘤大小,分级,组织学或Van Nuys预后指数与肿瘤细胞扩散之间未发现相关性。在2例中,观察到转移扩散到淋巴结中(pN1mi),而在1例中,检测到淋巴结中ITC。然而,SN阳性的原发灶的附加切片和免疫组织化学染色未显示浸润性癌。有趣的是,这三例患者均为BM阴性。诊断为DCIS的患者可能会发现肿瘤细胞扩散。这些细胞已经开始从浸润前乳腺病变或隐匿性浸润性肿瘤中扩散,或者代表了浸润前病变中微浸润的最早步骤。这些细胞的临床相关性必须进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号